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Abstract Sequential cleavage of amyloid precursor protein
(APP) by β- and γ-secretases and the formation of Aβ
peptides are pivotal for Alzheimer's disease. Therefore, a
large number of drugs has been developed targeting APP
metabolism. However, many pharmacological compounds
have been identified in vitro in immortalized APP over-
expressing cell lines rather than in primary neurons. Here,
we compared the effect of already characterized secretase
inhibitors and modulators on Aβ formation in primary
chicken telencephalic neurons and in a human neuroglioma
cell line (H4) ectopically expressing human APP with the
Swedish double mutation. Primary chicken neurons repli-
cated the effects of a β-secretase inhibitor (β-secretase
inhibitor IV), two γ-secretase inhibitors (DAPM, DAPT),
two non-steroidal-anti-inflammatory drugs (sulindac sul-
fide, CW), and of the calpain inhibitor calpeptin. With the
exception of the two γ-secretase inhibitors, all tested
compounds were more efficacious in primary chicken
telencephalic neurons than in the immortalized H4 cell
line. Moreover, H4 cells failed to reproduce the effect of
calpeptin. Hence, primary chicken telencephalic neurons
represent a suitable cell culture model for testing drugs
interfering with APP processing and are overall more
sensitive to pharmacological interference than immortalized
H4 cells ectopically expressing mutant human APP.
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Introduction
Alzheimer's disease (AD) is the most abundant age-related
form of dementia. Insoluble amyloid plaques consisting of
fibrillar Aβ42 aggregates are one of the hallmarks of
Alzheimer's pathology (Hardy and Selkoe 2002).
Aβ peptides are generated by β-a n dγ-secretase-
mediated cleavage of the amyloid precursor protein
(APP), whereas α-secretase activity produces only non-
amyloidogenic APP fragments and prevents Aβ produc-
tion (Haass 2004). The N-terminus of the Aβ domain is
cleaved by β-secretase (BACE-1), a step which is
essential for the formation of all Aβ peptides including
Aβ38, Aβ40, and Aβ42 (Cole and Vassar 2008). The
γ-secretase is a protein complex consisting of four
subunits, presenilin 1 (PS1) or PS2, APH-1a or APH-1b,
PEN-2, and nicastrin, and cuts APP at the intramembra-
nous C-terminal end of the Aβ domain (Wolfe 2006).
Aβ42 has the biophysical property to aggregate fast and to
form soluble oligomers as well as fibrillar structures, in
contrast to Aβ40 and other Aβ peptides (Dahlgren et al.
2002; Walsh and Selkoe 2007). Indeed, soluble Aβ42
oligomers were identified as major pathological source
causing neuronal toxicity and cognitive impairment (Haass
and Selkoe 2007). In humans, Aβ42 levels are elevated in
the cerebral cortex in both sporadic and familiar forms of
AD. Mutations either directly in the APP gene, such as the
Swedish double mutation at K595N/M596L in human
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Citron et al. 1995) or in presenilin genes (De Strooper
2007) elevate total Aβ42 content by increasing β-o r
γ-secretase-mediated APP cleavage. Thus, Aβ42 forma-
tion plays a pivotal role in AD.
In recent years, numerous pharmacological substances
have been developed that either inhibit or modulate
β-a n dγ-secretase activity to reduce Aβ production
(Ghosh et al. 2008;I m b i m b o2008;W o l f e2008;S i l v e s t r i
2009). However, many in vitro screens aiming to identify
substances that alter APP metabolism have been per-
formed in neuronal or non-neuronal cell lines highly
overexpressing human wildtype or mutant APP. In contrast
to immortalized cell lines, primary neurons produce
endogenous levels of APP, undergo differentiation, and
form functional synapses and thus exhibit a more
physiological system for drug testing.
Primary chicken neurons fulfill the criteria that are
required for analyzing APP processing. First, chicken
embryos express the long APP751 and APP695 variants
during development, which share 93% sequence identity
with human APP (Carrodeguas et al. 2005; Sarasa and
Pesini 2009). The human and chick Aβ42 sequences are
identical in contrast to rodent Aβ domains, which differ in
several amino acids from the human sequence. In addition,
chick embryos express the essential enzyme machinery
required for both amyloidogenic and non-amyloidogenic
processing of APP including α-, β-, and γ-secretases
(Carrodeguas et al. 2005; Sarasa and Pesini 2009). Indeed,
primary cultures of chicken telencephalic neurons secrete
detectable levels of Aβ1-38, Aβ1-40, Aβ1-42, and soluble
APP into their cell supernatant (Esselmann et al. 2004;
Leuchtenberger et al. 2009).
In this study, we examined primary chicken telencephal-
ic neurons and a human neuroglioma cell line overexpress-
ing human APP695 with the Swedish double mutation as
cell culture models for testing compounds that interfere
with APP processing. Therefore, substances previously
described to inhibit or modulate APP cleavage were
administered, and effects on Aβ38, Aβ40, and Aβ42
formation were evaluated.
Material and Methods
Materials
The following compounds were included in the study:
CW (3,5-bis(4-nitrophenoxy)benzoic acid), DAPM (N-
(N-3,5-difluorophenacetyl)-L-alanyl-S-phenylglycine
methyl ester), DAPT (N-[N-(3,5-difluorophenacetyl-L-
alanyl)]-S-phenylglycine t-butyl ester), calpeptin
(benzyloxycarbonylleucyl-norleucinal), sulindac sulfide
((Z)-5-fluoro-2-methyl-1-[p-(methylthio)benzylidene]
indene-3-acetic acid), and β-secretase inhibitor IV (all
Calbiochem). All compounds were dissolved in dimethyl
sulfoxide. The amount of vehicle was kept constant for all
concentrations of a respective compound.
For primary chicken telencephalic cultures, Nu Serum
was purchased from Becton Dickinson (BD). All other cell
medium components, unless indicated, were purchased
from Lonza.
Culture of Primary Embryonic Chicken Telencephalic
Neurons
Preparation of chicken telencephalic neurons was per-
formed according to Pettmann et al. 1979 with modifica-
tions. Embryonic day 8 (E8) embryos from fertilized
Lohman Brown hybrid chicken eggs were isolated, and
telencephalic neurons were mechanically dissociated using
a sterile nylon sieve with pore size 100 μM (BD Falcon).
Neurons were maintained in Dulbecco's Modified Eagles
Medium containing 4.5 g glucose/l, 5% Nu Serum, 0.01%
gentamicin, and 2 mM L-glutamine.
For the Aβ secretion assay, chicken neurons were plated
on poly-D-lysine pre-coated 24-well plates (BD Biocoat) at
a cell density of 1.8×10
6 neurons per 24 well. After 48 h,
culture medium was exchanged, and neurons were incubat-
ed for 24 h with different concentrations of compounds in a
total volume of 300 μl culture medium. For the MTT
viability assay, neurons were plated on poly-D-lysine pre-
coated 96-well plates (BD Biocoat) at a cell density of 3×
10
5 neurons per 96 well in a total volume of 160 μl culture
medium.
Culture of H4 Cells Ectopically Expressing Human
APPK595N/M596L
A human neuroglioma H4 cell line stably transfected with
the pAG3 vector containing human APP695 with the
Swedish double mutation K595N/M596L was used as cell
line model (Haugabook et al. 2001). The pAG3 vector is a
modified pcDNA3 plasmid and contains the hygromycin-B
resistance cassette with the transgene under the control of a
fused CMV and chicken β-actin promoter. H4 cells were
plated on 96-well plates (BD) at a cell density of 1×10
4
cells per 96 well in 160 μl OptiMEM (Invitrogen)
containing 10% fetal bovine serum, 1% penicillin/strepto-
mycin, 200 μg/ml hygromycin-B (Roth), and 2.5 μg/ml
blasticidin-S (BioChemika). After 48 h, culture medium
was exchanged and neurons were incubated for 24 h with
different concentrations of compounds in a total volume of
60 μl culture medium. All cultures were kept at 37°C and
5% CO2. Viability of cultures was determined by the MTT
assay (Gutmann et al. 2002).
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After treatment, cell supernatants were snap frozen at −80°C
and defrosted prior to Aβ measurement. At least three
separate wells were analyzed per experiment for each
condition.
Cell supernatants were examined for Aβ38, Aβ40, and
Aβ42 content with a commercially available Aβ-Triplex kit
from Mesoscale Discovery (MSD). Conditioned media of
primary chicken telencephalic cultures were measured
undiluted, whereas supernatants of H4 cells were diluted
1:10 with culture medium prior to measurement. For
capture, Aβ38, Aβ40, and Aβ42 specific antibodies
binding the C-terminus of the corresponding Aβ peptide
(provided by MSD) were used. Bound Aβ peptides were
detected with a monoclonal 6E10 antibody and quantified
by electrochemiluminescence. Aβ levels in cell super-
natants were evaluated in comparison to an Aβ peptide
standard in picogram or nanogram per milliliter. Vehicle-
treated control cultures were set as 100%. All data of
compound-treated cultures are displayed in relation to
vehicle-treated controls as mean±standard error of mean.
The total Aβ content was calculated as sum of Aβ38,
Aβ40, and Aβ42.
Data Analysis
GraphPad Prism (GraphPad Software, Inc., San Diego, CA)
was used to graph and analyze data.
Results
Aβ Peptides are Detectable in Conditioned Media
of Primary Chick Cultures and H4 Cells Expressing Human
APPK595N/M596L
Chicken embryos express endogenous APP in the devel-
oping telencephalon and also the required enzymes for Aβ
formation (Carrodeguas et al. 2005). Hence, we first
determined the amount of Aβ38, Aβ40, and Aβ42 being
released into the cell supernatant by primary E8 chicken
telencephalic neurons and H4 cells stably expressing
human APPK595N/M596L.
Primary chicken neurons were cultured in 24-well
plates at high cell density for 48 h. For determining Aβ
production, 300 μl of fresh medium were applied for
24 h. H4 cells overexpressing human APPK595N/M596L
were plated in 96-well plates and grown to 80–90%
confluency. Cells were then incubated with 60 μlo ff r e s h
medium for 24 h. Conditioned media of cultures were then
analyzed for all three Aβ analytes using a Triplex
immunosorbent assay.
Both culture systems released Aβ38, Aβ40, and Aβ42
peptides at detectable levels (Fig. 1a, b). H4 cells over-
expressing human APPK595N/M596L secreted 1.7±0.1 ng/ml
Aβ38, 24±1.0 ng/ml Aβ40, and 1.9±0.1 ng/ml Aβ42
(27.8±1.0 ng/ml total Aβ), whereas primary telencephalic
neurons produced 0.11±0.01 ng/ml Aβ38, 1.37±0.06
ng/ml Aβ40, and 0.17±0.01 ng/ml Aβ42 (1.64±0.08 ng/
ml total Aβ). The Aβ content in cell free culture medium
was negligible (data not shown). Thus, the H4 cell line
produced at least tenfold more Aβ peptides than primary
telencephalic chicken neurons.
However, the relative abundance of different Aβ
peptides was comparable between cultures of primary
neurons and the H4 cell line. The main Aβ species detected
in conditioned media was Aβ40, which comprised more
than 80% of all analyzed Aβ forms. Aβ38 and Aβ42 were
produced considerably less than Aβ40 but both in similar
quantities at approximately 7–10%. Importantly, the relative
Fig. 1 Immortalized cell line produces more Aβ peptides than
primary neurons in vitro. a The H4 neuroglioma cell line over-
expressing human APPK595N/M596L was assessed for ectopic Aβ
production by an immunosorbent assay. The H4 cell line generated
more Aβ38, Aβ40, and Aβ42 peptides in a 24-h time period than
primary neurons. Aβ40 was the predominant Aβ peptide. b Super-
natants of primary telencephalic chicken neurons were examined for
endogenous Aβ production by an immunosorbent assay. Primary
neurons secreted detectable amounts of Aβ38, Aβ40, and Aβ42
peptides in a 24-h time period. Aβ40 was the predominant Aβ
peptide. Graphs represent the individual Aβ content as mean±
standard error of mean in nanogram per milliliter
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correlates with results from previously described primary
chicken telencephalic cultures (Esselmann et al. 2004).
Hence, primary chicken telencephalic neurons and H4 cells
stably transfected with human APPK595N/M596L produced
sufficient amounts of Aβ38, Aβ40, and Aβ42 peptides and
could be used for further analysis.
To compare the effect of drugs modulating or inhibiting
the generation of Aβ38, Aβ40, and Aβ42 peptides in
cultures of primary chick neurons and in the H4 neuro-
glioma cell line, we examined already characterized β- and
γ-secretase inhibitors, non-steroidal anti-inflammatory
drugs (NSAIDs), and a calpain inhibitor. Almost all of the
selected compounds were demonstrated to alter APP
processing but not total APP protein levels (Dovey et al.
2001; Weggen et al. 2001; Mathews et al. 2002; Na et al.
2007). Hence, supernatants of compound-treated cultures
were analyzed for their Aβ38, Aβ40, and Aβ42 content by
an immunosorbent assay assuming that total APP levels
remained unaffected. Viability of cultures was assessed in a
colorimetric MTT assay. The respective IC50 and Emax of
each compound are summarized in Table 1.
BACE-1 Inhibition is More Potent in Primary Neurons
than in the H4 Cell Line Expressing Human APP
with the Swedish Double Mutation
First, we examined the β-secretase inhibitor IV, a commer-
cially available BACE-1 inhibitor, which has been previ-
ously shown to inhibit BACE-1 in a HEK cell culture
model overexpressing APPNFEV at an IC50 of 15 nM
(Stachel et al. 2004). When the β-secretase inhibitor IV
was applied on the H4 cell line, a concentration-
dependent decrease in Aβ secretion (IC50 Aβ38=92.3
nM, IC50 Aβ40=124.7 nM, IC50 Aβ42=215.6 nM) was
evident (Fig. 2a), but the reduction occurred at distinctly
higher concentrations than in the HEK cell culture model
(Stachel et al. 2004). In contrast, the Aβ38, Aβ40, and
Aβ42 content declined in primary neuronal cultures
already at 5 nM (Fig. 2b), and Aβ42 was reduced by
more than 50% at an inhibitor concentration of 25 nM,
indicating that the extent of inhibition in telencephalic
neurons complies with the reported IC50 in HEK cells
(Stachel et al. 2004). Unexpectedly, Aβ40 and Aβ42
production was not completely inhibited by the BACE-1
inhibitor (Table 1). The effect of the β-secretase inhibitor
on Aβ cleavage was not due to compound toxicity as no
reduction in cell viability was observed (data not shown).
Altogether, BACE-1 inhibition was approximately tenfold
more potent in primary cells than in the human neuro-
glioma cell line expressing human APPK595N/M596L.
γ-Secretase Inhibition is More Pronounced in the H4
Neuroglioma Cell Line
Next, we addressed the effect of two γ-secretase
inhibitors, DAPM and DAPT, in our two culture models.
DAPM was shown to reduce secretion of Aβ monomers
in CHO cells expressing human APP751Val717Phe at an
IC50 of approximately 100 nM by a highly sensitive
immunoprecipitation and western blotting method (Walsh
et al. 2002) .D A P Tw a sr e p o r t e dt oa b o l i s hA β42
formation in primary human neuronal cultures at an IC50
of 200 nM (Dovey et al. 2001).
Table 1 Effects of pharmacological modulators on Aβ formation
Aβ38 Aβ40 Aβ42
IC50 Emax IC50 Emax IC50 Emax
Beta secretase inhibitor IV H4 cells—hAPPK595N/N596L 92 nM 88% 125 nM 79% 216 nM 86%
Primary chicken neurons 3.7 nM 91% 4.7 nM 76% 4.8 nM 70%
DAPM H4 cells—hAPPK595N/N596L 20 nM 100% 23 nM 100% 26 nM 100%
Primary chicken neurons 63 nM 100% 100 nM 100% 107 nM 100%
DAPT H4 cells—hAPPK595N/N596L 50 nM 100% 61 nM 100% 64 nM 100%
Primary chicken neurons 75 nM 100% 93 nM 100% 101 nM 100%
Sulindac sulfide H4 cells—hAPPK595N/N596L –– –– 76 μM 100%
Primary chicken neurons –– –– 33 μM 100%
CW H4 cells—hAPPK595N/N596L –– –– 41 μM 100%
Primary chicken neurons –– –– 17 μM 100%
Calpeptin H4 cells—hAPPK595N/N596L 4.0 μM 100% 7.4 μM 100% ––
Primary chicken neurons 5.0 μM 100% –– ––
The IC50 and Emax values for Aβ38, Aβ40, and Aβ42 generation in H4 cells overexpressing human APPK595N/M596L and in primary telencephalic
chicken neurons are summarized for each individual compound
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H4 cells (IC50 Aβ38=19.9 nM, IC50 Aβ40=23.1 nM,
IC50 Aβ42=25.9 nM) but conversely caused an increase
of all three Aβ forms at low nanomolar concentrations
(Fig. 3a). In cultures of primary telencephalic neurons,
DAPM also decreased formation of Aβ peptides (IC50
Aβ38=61.9 nM, IC50 Aβ40=99.7 nM, IC50 Aβ42=
106.9 nM) but at higher concentrations than in H4
cultures. Also, no increase in Aβ secretion was observed
in primary cultures at any concentration of the γ-secretase
inhibitor (Fig. 3b). Hence, the effect of DAPM was
slightly more potent in H4 cells overexpressing human
APPK595N/M596L than in primary telencephalic neurons.
DAPM had no effect on cell viability in both culture
systems (data not shown).
The second γ-secretase inhibitor, DAPT, inhibited APP
cleavage in H4 cells (IC50 Aβ38=50.3 nM, IC50 Aβ40=
61.4 nM, IC50 Aβ42=63.8 nM) but also increased the
formation of all three Aβ species at 10 nM (Fig. 4a).
Similarly, Aβ38, Aβ40, and Aβ42 peptide levels decreased
in supernatants of primary neurons (IC50 Aβ38=71.2 nM,
IC50 Aβ40=92.8 nM, IC50 Aβ42=100.8 nM), but no
dramatic increase in Aβ levels was observed at low
nanomolar concentrations of the compound in contrast to
H4 cells (Fig. 4b). Viability of primary neurons and H4
cells was not affected by DAPT treatment (data not shown).
As in DAPM treated cultures, the effect of DAPT was
slightly more pronounced in H4 cells stably expressing
human APPK595N/M596L than in primary telencephalic
neurons. However, the IC50 of DAPT and DAPM for
Fig. 2 BACE-1 inhibition is more efficacious in primary neurons. H4
cells overexpressing human APPK595N/M596L and primary telencephal-
ic chicken neurons were treated with different concentrations of the
β-secretase inhibitor IV for 24 h. Aβ content of cell supernatants was
determined by an immunosorbent assay. a In H4 cells, levels of Aβ38,
Aβ40, and Aβ42 peptides decreased in a concentration-dependent
manner. b In primary telencephalic neurons, Aβ38, Aβ40, and Aβ42
levels declined already dramatically at low nanomolar concentrations
of the BACE-1 inhibitor, in contrast to H4 cells. Graphs represent the
individual Aβ content in percent of vehicle-treated cultures as mean±
standard error of mean
Fig. 3 The γ-secretase inhibitor DAPM reduces Aβ formation in
both culture models. H4 cells overexpressing human APPK595N/M596L
and primary telencephalic chicken neurons were treated with different
concentrations of the γ-secretase inhibitor DAPM for 24 h. Aβ
content of cell supernatants was determined by an immunosorbent
assay. a Levels of Aβ38, Aβ40, and Aβ42 peptides declined
dramatically starting at a concentration of 50 nM DAPM in the H4
cell line. b Aβ38, Aβ40, and Aβ42 content decreased at a
concentration of 50 nM DAPM in primary neurons but not as
pronounced as in the H4 cell line. Graphs represent the individual Aβ
content in percent of vehicle-treated cultures as mean±standard error
of mean
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compared to the published efficacies of these inhibitors.
Hence, both culture systems reproduced the reported effects
of the selected γ-secretase inhibitors.
Two NSAIDs Modulate Processing of Aβ Peptides
in Primary Neurons at Lower Concentrations
than in the H4 Cell Line
A subset of non-steroidal anti-inflammatory drugs (NSAIDs)
has been shown to interfere with APP processing by
modulating γ-secretase-mediated APP cleavage independent
of their impact on cyclooxygenase-1 (COX1) and COX2
activity(Weggenetal.2001). Here, we investigated the effect
of sulindac sulfide and CW in our cell culture models. The
non-selective COX-inhibitor sulindac sulfide has previously
been reported to reduce Aβ42 levels by ≥50% at concen-
trations of 80–100 μM in several cell lines overexpressing
human wildtype or mutant APP (Weggen et al. 2001).
Concomitant with the decrease in Aβ42 content, an increase
in Aβ38 was detected in supernatants of treated cultures
(Weggen et al. 2001). In CHO cells expressing human APP
containing the Swedish mutation, 40 μMs u l i n d a cs u l f i d e
reduced Aβ42 secretion to ~45% (Weggen et al. 2003). The
second NSAID we examined was the cell-permeable
benzoate CW, which was identified in a computer-based
structural similarity search for NSAIDs. CW has been
demonstrated to reduce Aβ42 levels at a concentration of
100 μM (Okochi et al. 2006).
In H4 cells expressing human APPK595N/M596L, sulindac
sulfide enhanced generation of Aβ38 peptides at low
micromolar concentration (Fig. 5a). A decrease in Aβ42
levels appeared at a concentration of 50 μM with Aβ42
levels being reduced to 75.0±7.1%. The Aβ42 content
declined further to 39.3±2.0% at 100 μM, whereas Aβ40
production remained still unaltered. At 150 μM, sulindac
sulfide started to display already some minor cell toxicity in
the viability assay (data not shown). Thus, the concentra-
tion of sulindac sulfide necessary to diminish Aβ42 levels
by 50% was between 75 and 100 μM. The different extent
of sulindac sulfide-mediated modulation of Aβ38 and
Aβ42 levels was not unexpected. Analyses of different
PS1 mutations associated with familial Alzheimer's disease
(FAD) revealed that sulindac sulfide can modulate Aβ38
and Aβ42 formation independently (Page et al. 2008).
In contrast to H4 cells, secretion of Aβ42 peptides was
already reduced at lower micromolar concentrations of
sulindac sulfide in primary neuronal cultures (Fig. 5b).
Aβ38 content started to increase at 25 μM to approximate-
ly 149.7±6.4%, whereas Aβ42 levels decreased concomi-
tantly to 54.7±6.4%. At 50 μM, Aβ38 levels did not rise
any further, but Aβ42 continued to drop to 25.3±2.1%, and
also Aβ40 levels started to decline. At concentrations
beginning with 75 μM, the NSAID started to become toxic
in primary cultures (data not shown). Hence, the concen-
tration of sulindac sulfide required to reduce Aβ42 levels in
primary chick cultures by 50% is at ~33 μM. This also
complies with the efficacy of sulindac sulfide described in
HEK cell (Weggen et al. 2003), whereas sulindac sulfide
was surprisingly less efficacious in the stable H4 cell line
expressing human APPK595N/M596L.
CW started to elevate Aβ38 and moderately reduce
Aβ42 levels in H4 cells at a concentration of 50 μM
(Fig. 6a). At 100 μM, Aβ38 increased to 287.5±31.2%,
whereas Aβ42 was further reduced to 16.0±1.8% com-
pared to vehicle-treated cultures. At 150 and 200 μM,
Aβ38 and Aβ40 secretion started also to decline, although
no cell toxicity was observed in the MTT viability assay at
these concentrations (data not shown). Therefore, CW
Fig. 4 The γ-secretase inhibitor DAPT reduces Aβ formation in
primary and immortalized cells. H4 cells overexpressing human
APPK595N/M596L and primary telencephalic chicken neurons were
treated with different concentrations of the γ-secretase inhibitor DAPT
for 24 h. Aβ content of cell supernatants was determined by an
immunosorbent assay. a In the H4 cell line, Aβ38, Aβ40, and Aβ42
levels started to be reduced at a concentration of 50 nM DAPT. b In
primary telencephalic neurons, Aβ peptides started to diminish at a
concentration of 100 nM DAPT. Graphs represent the individual Aβ
content in percent of vehicle-treated cultures as mean±standard error
of mean
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trations between 50 and 100 μM.
In cultures of primary telencephalic neurons, moderate
changes in Aβ38 and Aβ42 peptide were already detected
at 5 μM CW (Fig. 6b). At 10 μM, an increase of 127.9±
0.9% Aβ38 was observed, whereas Aβ42 levels declined
to 63.6±2.4%. The effect of CW was further potentiated at
50 μM, with Aβ38 levels rising to 159.3±8.0% and Aβ42
falling to 29.9±1.2%. Therefore, CW diminished Aβ42
levels by 50% at ~17 μM in primary neurons. The Aβ40
content remained unchanged up to 50 μM compared to
vehicle-treated cells. However, starting from 100 μM,
levels of all Aβ species declined progressively with
increasing concentration of the NSAID. The reduction of
Aβ species at the two highest concentrations was due to
neuronal toxicity of the compound as CW affected cell
viability at 150 and 200 μM but not at lower concentrations
(data not shown). As sulindac sulfide, CW was also more
efficacious in modulating APP processing in primary
telencephalic neurons than in the H4 cell line ectopically
expressing human mutant APP.
Interfering with Calpain Signaling Affects Aβ42 Formation
Only in Primary Chicken Neurons
An unregulated intracellular increase of Ca
2+ and elevated
activity of the Ca
2+-dependent calpain proteases has been
linked with inducing cell death (Harwood et al. 2005;
Golstein and Kroemer 2007). Further, calpain inhibitors
have been demonstrated to counteract excitotoxic insults
(Hara and Snyder 2007). But besides their role in cell death,
calpains have also been implicated in APP processing since
inhibition of calpain activity was demonstrated to increase
Fig. 5 Sulindac sulfide modulates Aβ processing more efficaciously
in primary neurons than in the H4 cell line. H4 cells overexpressing
human APPK595N/M596L and primary telencephalic chicken neurons
were treated with different concentrations of the NSAID sulindac
sulfide for 24 h. Aβ content of cell supernatants was determined by an
immunosorbent assay. a In the H4 cell line, Aβ42 levels started to
decline at a concentration of 50 μM. b In primary telencephalic
neurons, Aβ42 levels dropped already at a concentration of 25 μM.
The blue bar indicates toxic concentrations. Graphs represent the
individual Aβ content in percent of vehicle-treated cultures as mean±
standard error of mean
Fig. 6 Compound CW modulates Aβ42 formation at lower
concentrations in primary neurons than in the H4 cell line.
Different concentrations of the non-steroidal anti-inflammatory
drug CW were administered in cultures of H4 cells overexpressing
human APPK595N/M596L and primary telencephalic chicken neurons.
Cell supernatants were assessed for Aβ content by an immunosor-
bent assay. a In the H4 cell line, Aβ42 levels started to diminish at a
concentration of 50 μM. b In primary telencephalic neurons, Aβ42
levels started to decrease already at a concentration of 5 μM. The
blue bar indicates toxic concentrations. Graphs represent the
individual Aβ content in percent of vehicle-treated cultures as
m e a n ± s t a n d a r de r r o ro fm e a n
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et al. 1999; Mathews et al. 2002). The cell-permeable
calpain inhibitor calpeptin has been reported to elevate
secretion of Aβ42 but not of Aβ40 at a concentration of
10 μM in a murine cell line ectopically expressing human
wildtype APP695 and also in untransfected murine cells
(Mathews et al. 2002).
Calpeptin did not evoke any dramatic changes in H4
cells expressing mutant human APP up to a concentration
of 1 μM (Fig. 7a). However, at 10 μM, Aβ38 (12.9±2.6%)
and Aβ40 (35.5±2.2%) peptide levels decreased sharply,
whereas Aβ42 (90.3±6.0%) remained almost on the same
level as in vehicle control cultures.
Similarly,noeffectofcalpeptinwasobservedinculturesof
primary chicken neurons up to a concentration of 1 μM
(Fig. 7b). In contrast to H4 cells, calpeptin increased Aβ42
levels to 259.3±7.3% at a concentration of 10 μM, whereas
Aβ40 remained almost unchanged at 89.9±3.8%. The Aβ38
content in supernatants was reduced to 31.1±1.8%. No
toxicity of calpeptin was observed in primary and H4 cell
cultures (data not shown). Hence, primary telencephalic
neurons but not H4 cells expressing human APPK595N/M596L
increased Aβ42 generation at a calpeptin concentration of
10 μM. Therefore, primary chicken neurons but not H4 cells
reproduced the previously reported effect of calpeptin on
APP processing (Mathews et al. 2002).
Discussion
Increased formation of toxic Aβ42 peptides is characteristic
for sporadic and familial forms of Alzheimer's disease.
Therefore, compounds targeting β- and γ-secretase activ-
ities were developed in recent years to render formation of
aberrant Aβ42. Most in vitro screens identifying such
compounds were performed in immortalized cells express-
ing mutant human APP. Here, we compared primary
chicken telencephalic neurons with a human neuroglioma
cell line overexpressing human APP harboring the Swedish
double mutation to decipher differences in their response to
known modulators of APP processing.
We chose chicken telencephalic rather than rodent
neurons as source for primary cultures since chick Aβ42
is identical to the human sequence and primary chicken
telencephalic neurons were previously demonstrated to
secrete detectable amounts of Aβ1-37, Aβ1-38, Aβ1-39,
Aβ1-40, and Aβ1-42 in vitro by using an immunoprecip-
itation and Western Blot protocol (Esselmann et al. 2004).
In accordance, we confirmed formation of Aβ38, Aβ40,
and Aβ42 peptides in cell supernatants of primary chicken
telencephalic neurons using an electrochemiluminescence
based immunosorbent assay. Similar to human cerebrospi-
nal fluid (Lewczuk et al. 2004), Aβ40 was the predominant
Aβ species produced by primary chicken neurons and the
neuroglioma cell line. H4 cells overexpressing human
mutant APP secreted at least tenfold more Aβ peptides
than chicken neurons, but the Aβ42/Aβ40 ratio was
comparable in supernatants of H4 cells and primary
telencephalic neurons.
Since both culture systems produced desirable levels of
Aβ peptides, we administered compounds known to inhibit
or modulate APP cleavage and determined production of
Aβ38, Aβ40, and Aβ42 peptides.
In cultures treated with the β-secretase inhibitor IV, we
observed a more severe inhibition of β-secretase activity in
primary neurons than in the H4 cell line expressing human
APP harboring the Swedish double mutation. This appears
particularly interesting as this mutation has been associated
with accelerated APP cleavage by β-secretase. Other
groups also demonstrated that BACE-1 inhibition is
approximately tenfold less powerful in cells expressing
Fig. 7 Calpain inhibition increases Aβ42 formation in primary but not
immortalized cells. H4 cells overexpressing human APPK595N/M596L and
primary telencephalic chicken neurons were treated with different
concentrations of calpeptin for 24 h. Aβ content of cell supernatants
was determined by an immunosorbent assay. a No modulation of Aβ42
levels was observed in H4 cells. b In contrast, Aβ42 content was
increased at 10 μM in primary neuronal cultures. Graphs represent the
individual Aβ content in percent of vehicle-treated cultures as mean±
standard error of mean
264 J Mol Neurosci (2011) 43:257–267human APPK595N/M596L compared to cells overexpressing
wildtype APP (Hussain et al. 2007; Yamakawa et al. 2010).
Recently, the difference in β-secretase inhibition has been
linked to different subcellular localization of wildtype APP
and APPK595N/M596L (Koo and Squazzo 1994; Haass et al.
1995; Yamakawa et al. 2010). Similarly, the FAD-linked
mutations APPV717F, PS1M146L, and PS1L166P, which all
affect γ-secretase cleavage, are less sensitive to γ-secretase
inhibitors (Xia et al. 2000; Czirr et al. 2007). Moreover,
cells transfected with APPV717F or different PS1 mutations
display altered secretion of Aβ peptides in response to
sulindac sulfide treatment compared to cells transfected
with the respective wildtype protein (Weggen et al. 2003;
Czirr et al. 2007;P a g ee ta l .2008). Thus, secretase
inhibitors and modulators exhibit different potencies and
effects in cellular assays depending on the presence or
absence of FAD-linked mutations. Since the vast majority
of patients who suffer from sporadic AD encode wildtype
and not mutant APP or PS1, screening compounds in cells
expressing wildtype APP and PS1 reflects more on human
pathology and also defines the efficacy of a substance more
precisely.
Both γ-secretase inhibitors, DAPM and DAPT,
evoked a dose-dependent decrease in Aβ38, Aβ40, and
Aβ42 levels, but the reduction was more pronounced in
the neuroglioma cell line than in primary telencephalic
neurons. Indeed, DAPT has been demonstrated to inhibit
Aβ formation more severely in a HEK293 cell line
expressing human APP751 containing the Swedish
mutation than in primary neuronal cultures with DAPT
exhibiting a five- to tenfold lower potency in human and
mouse primary cultures (Dovey et al. 2001). Similarly to
DAPT, a selective tyrosine kinase inhibitor, which has
been suggested to indirectly regulate γ-secretase activity,
reduced Aβ production faster in N2a cells producing
Swedish mutant APP than in primary cortical neurons
(Netzer et al. 2003). As β-secretase cleavage is a pre-
requisite for γ-secretase-mediated APP processing, APP
containing the Swedish mutation simply increases the
intracellular concentration of γ-secretase substrate and
thus provides a higher and more favorable substrate/
enzyme ratio than in primary neurons (Citron et al. 1992;
Yang et al. 2003). Subsequently, an enzymatic reaction at a
high substrate/enzyme ratio enables a more efficient
inhibition of APP cleavage by secretase inhibitors. A
comparison of γ-secretase inhibitors in cell lines express-
ing either wildtype or APP containing the Swedish
mutation would address the influence of Swedish mutant
APP on γ-secretase inhibition. When DAPT was admin-
istered in vivo, the actual concentration of DAPT in brain
tissue (~200 nM and higher) that reduced total Aβ content
w a si ne x c e s so ft h eI C 50 in primary cultures (IC50 Aβ
total=115 nM) (Dovey et al. 2001). Thus, in vivo DAPT
data indicate that primary neurons are more likely to
define the potency of a γ-secretase inhibitor for in vivo
administration than cell lines. Beside the reduction in Aβ
levels, we also observed an increase in Aβ38, Aβ40, and
Aβ42 formation at DAPM and DAPT concentrations
below their respective IC50.S u c ha ne f f e c th a sa l r e a d y
been described for a difluoroketoamide-based γ-secretase
inhibitor, which also increased Aβ42 levels at sub-
inhibitory concentrations (Durkin et al. 1999).
In contrast, modulation of γ-secretase activity by
NSAIDs appeared more severe in primary cultures. A
comparison of N2a cells expressing human APP bearing
the Swedish mutation and primary rat cortical neurons
also indicated a stronger reduction of Aβ40 and Aβ42
levels in primary cultures at a concentration of 25 μM
(Gasparini et al. 2004), although we only observed a
r e d u c t i o ni nA β40 levels at very high sub-lethal and lethal
concentrations. The reduced potency of NSAIDs in the
neuroglioma cell line is, unlike BACE-1 inhibitors,
independent of the APP Swedish double mutation. CHO
cells transfected with APPK595N/M596L secrete the same
levels of Aβ42 after treatment with sulindac sulfide as
cells expressing wildtype APP (Weggen et al. 2003).
However, primary neurons and cell lines differ in their
APP content. Whereas primary neurons produce endoge-
nous APP at physiological levels, cell lines highly over-
express ectopic APP suggesting that the modulating
activity of NSAIDs is dependent on the amount and
availability of APP substrate. Such a scenario would
assume that sulindac sulfide and CW directly interact with
APP. Indeed, a study using labeled γ-secretase modulators
(GSM) revealed a direct interaction of GSMs with residues
of the beta-amyloid peptide rather than with the core
proteins of the γ-secretase complex (Kukar et al. 2008).
Hence, total APP levels can be critical for the potency of
NSAIDs. Besides their higher sensitivity for APP modu-
lation, primary neurons are also more prone to cell toxicity
mediated by NSAIDs and give, in addition to APP
processing, valuable information on the neurotoxicity of
substances.
Further, we analyzed the calpain inhibitor calpeptin in
our culture models. Interestingly, we replicated the Aβ42
increasing effect of calpeptin in primary cultures but not in
the H4 cell line although the modulating activity of
calpeptin was initially demonstrated in a murine
fibroblast-like cell line and in murine and human neuro-
blastoma cells (Mathews et al. 2002). Hence, the lack of
effect of calpeptin in H4 cells can be attributed at least in
parts to the nature of the H4 neuroglioma cell line. This
finding highlights the problem that most data on APP
processing has been generated in a variety of different cell
lines and hence a comparison between cellular assays
proves difficult. Some cell lines originate from non-
J Mol Neurosci (2011) 43:257–267 265neuronal cell types, whereas others are from different
species. Also, the expression of various FAD-linked
mutations in cell lines does not allow a comprehensive
comparison of secretase inhibitors and modulators. There-
fore, the use of a unifying cell culture system such as
primary neurons would be of advantage to allow a direct
comparison of APP modifying substances.
In conclusion, primary telencephalic chicken neurons are
a well-suited cell culture model for testing drugs targeting
Aβ formation. Primary chicken neurons produce endoge-
nous levels of wildtype APP and PS1 and secrete Aβ
peptides which are identical in their sequence to human Aβ
and thus reflect the molecular condition of sporadic
Alzheimer's disease. In addition, primary telencephalic
neurons are overall more sensitive to pharmacological
intervention than immortalized cell lines with the exception
of γ-secretase inhibitors and in sum define the potency and
mechanism of drugs more accurately regarding their in vivo
efficacy and toxicity. For drug discovery, primary neurons
expressing wildtype APP are a suitable system to model
sporadic Alzheimer's disease. In contrast, cell lines produc-
ing proteins containing FAD-linked mutations exhibit a
model for testing drugs targeting familial forms of AD.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Carrodeguas JA, Rodolosse A, Garza MV et al (2005) The chick
embryo appears as a natural model for research in beta-amyloid
precursor protein processing. Neuroscience 134:1285–1300
Citron M, Oltersdorf T, Haass C et al (1992) Mutation of the beta-
amyloid precursor protein in familial Alzheimer's disease
increases beta-protein production. Nature 360:672–674
Citron M, Teplow DB, Selkoe DJ (1995) Generation of amyloid beta
protein from its precursor is sequence specific. Neuron 14:661–
670
Cole SL, Vassar R (2008) The role of amyloid precursor protein
processing by BACE1, the beta-secretase, in Alzheimer disease
pathophysiology. J Biol Chem 283:29621–29625
Czirr E, Leuchtenberger S, Dorner-Ciossek C et al (2007)
Insensitivity to Abeta42-lowering nonsteroidal anti-
inflammatory drugs and gamma-secretase inhibitors is com-
mon among aggressive presenilin-1 mutations. J Biol Chem
282:24504–24513
Dahlgren KN, Manelli AM, Stine WB et al (2002) Oligomeric and
fibrillar species of amyloid-beta peptides differentially affect
neuronal viability. J Biol Chem 277:32046–32053
De Strooper B (2007) Loss-of-function presenilin mutations in
Alzheimer disease. Talking point on the role of presenilin
mutations in Alzheimer disease. EMBO Rep 8:141–146
Dovey HF, John V, Anderson JP et al (2001) Functional gamma-
secretase inhibitors reduce beta-amyloid peptide levels in brain. J
Neurochem 76:173–181
Durkin JT, Murthy S, Husten EJ et al (1999) Rank-order of potencies
for inhibition of the secretion of abeta40 and abeta42 suggests
that both are generated by a single gamma-secretase. J Biol Chem
274:20499–20504
Esselmann H, Maler JM, Kunz N et al (2004) Lithium decreases
secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/
40 in chicken telencephalic cultures but specifically increases
intracellular Abeta1-38. Neurodegener Dis 1:236–241
Gasparini L, Rusconi L, Xu H et al (2004) Modulation of beta-
amyloid metabolism by non-steroidal anti-inflammatory drugs in
neuronal cell cultures. J Neurochem 88:337–348
Ghosh AK, Gemma S, Tang J (2008) Beta-secretase as a therapeutic
target for Alzheimer's disease. Neurotherapeutics 5:399–408
Golstein P, Kroemer G (2007) Cell death by necrosis: towards a
molecular definition. Trends Biochem Sci 32:37–43
Gutmann B, Hutter-Paier B, Skofitsch G et al (2002) In vitro models
of brain ischemia: the peptidergic drug cerebrolysin protects
cultured chick cortical neurons from cell death. Neurotox Res
4:59–65
Haass C (2004) Take five—BACE and the gamma-secretase quartet
conduct Alzheimer's amyloid beta-peptide generation. Embo J
23:483–488
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neuro-
degeneration: lessons from the Alzheimer's amyloid beta-peptide.
Nat Rev Mol Cell Biol 8:101–112
Haass C, Lemere CA, Capell A et al (1995) The Swedish mutation
causes early-onset Alzheimer's disease by beta-secretase cleavage
within the secretory pathway. Nat Med 1:1291–1296
Hara MR, Snyder SH (2007) Cell signaling and neuronal death. Annu
Rev Pharmacol Toxicol 47:117–141
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's
disease: progress and problems on the road to therapeutics.
Science 297:353–356
Harwood SM, Yaqoob MM, Allen DA (2005) Caspase and calpain
function in cell death: bridging the gap between apoptosis and
necrosis. Ann Clin Biochem 42:415–431
Haugabook SJ, Yager DM, Eckman EA et al (2001) High throughput
screens for the identification of compounds that alter the
accumulation of the Alzheimer's amyloid beta peptide (Abeta).
J Neurosci Methods 108:171–179
Hussain I, Hawkins J, Harrison D et al (2007) Oral administration of a
potent and selective non-peptidic BACE-1 inhibitor decreases
beta-cleavage of amyloid precursor protein and amyloid-beta
production in vivo. J Neurochem 100:802–809
Imbimbo BP (2008) Therapeutic potential of gamma-secretase
inhibitors and modulators. Curr Top Med Chem 8:54–61
Klafki H, Abramowski D, Swoboda R et al (1996) The carboxyl
termini of beta-amyloid peptides 1-40 and 1-42 are generated by
distinct gamma-secretase activities. J Biol Chem 271:28655–
28659
Koo EH, Squazzo SL (1994) Evidence that production and release of
amyloid beta-protein involves the endocytic pathway. J Biol
Chem 269:17386–17389
Kukar TL, Ladd TB, Bann MA et al (2008) Substrate-targeting
gamma-secretase modulators. Nature 453:925–929
Leuchtenberger S, Maler J, Czirr E et al (2009) Nonsteroidal anti-
inflammatory drugs and ectodomain shedding of the amyloid
precursor protein. Neurodegener Dis 6:1–8
Lewczuk P, Esselmann H, Otto M et al (2004) Neurochemical
diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/
Abeta40 ratio and total tau. Neurobiol Aging 25:273–281
Mathews PM, Jiang Y, Schmidt SD et al (2002) Calpain activity
regulates the cell surface distribution of amyloid precursor
protein. Inhibition of calpains enhances endosomal generation
of beta-cleaved C-terminal APP fragments. J Biol Chem
277:36415–36424
266 J Mol Neurosci (2011) 43:257–267Mullan M (1992) Familial Alzheimer's disease: second gene locus
located. Bmj 305:1108–1109
Mullan M, Houlden H, Windelspecht M et al (1992) A locus for
familial early-onset Alzheimer's disease on the long arm of
chromosome 14, proximal to the alpha 1-antichymotrypsin gene.
Nat Genet 2:340–342
Na CH, Jeon SH, Zhang G et al (2007) Inhibition of amyloid beta-
peptide production by blockage of beta-secretase cleavage site of
amyloid precursor protein. J Neurochem 101:1583–1595
Netzer WJ, Dou F, Cai D et al (2003) Gleevec inhibits beta-amyloid
production but not Notch cleavage. Proc Natl Acad Sci U S A
100:12444–12449
Okochi M, Fukumori A, Jiang J et al (2006) Secretion of the Notch-1 Abeta-
like peptide during Notch signaling. J Biol Chem 281:7890–7898
Page RM, Baumann K, Tomioka M et al (2008) Generation of
Abeta38 and Abeta42 is independently and differentially affected
by familial Alzheimer disease-associated presenilin mutations
and gamma-secretase modulation. J Biol Chem 283:677–683
Pettmann B, Louis JC, Sensenbrenner M (1979) Morphological and
biochemical maturation of neurones cultured in the absence of
glial cells. Nature 281:378–380
Sarasa M, Pesini P (2009) Natural non-transgenic animal models for
research in Alzheimer's disease. Curr Alzheimer Res 6:171–178
Silvestri R (2009) Boom in the development of non-peptidic beta-
secretase (BACE1) inhibitors for the treatment of Alzheimer's
disease. Med Res Rev 29:295–338
Stachel SJ, Coburn CA, Steele TG et al (2004) Structure-based design
of potent and selective cell-permeable inhibitors of human beta-
secretase (BACE-1). J Med Chem 47:6447–6450
Walsh DM, Selkoe DJ (2007) A beta oligomers—a decade of
discovery. J Neurochem 101:1172–1184
Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted
oligomers of amyloid beta protein potently inhibit hippocampal
long-term potentiation in vivo. Nature 416:535–539
Weggen S, Eriksen JL, Das P et al (2001) A subset of NSAIDs lower
amyloidogenic Abeta42 independently of cyclooxygenase activ-
ity. Nature 414:212–216
Weggen S, Eriksen JL, Sagi SA et al (2003) Evidence that
nonsteroidal anti-inflammatory drugs decrease amyloid beta 42
production by direct modulation of gamma-secretase activity. J
Biol Chem 278:31831–31837
Wolfe MS (2006) The gamma-secretase complex: membrane-
embedded proteolytic ensemble. Biochemistry 45:7931–7939
Wolfe MS (2008) Gamma-secretase inhibition and modulation for
Alzheimer's disease. Curr Alzheimer Res 5:158–164
Xia W, Ostaszewski BL, Kimberly WT et al (2000) FAD mutations in
presenilin-1 or amyloid precursor protein decrease the efficacy of
a gamma-secretase inhibitor: evidence for direct involvement of
PS1 in the gamma-secretase cleavage complex. Neurobiol Dis
7:673–681
Yamakawa H, Yagishita S, Futai E et al (2010) Beta-secretase
inhibitor potency is decreased by aberrant beta-cleavage location
of the "Swedish mutant" amyloid precursor protein. J Biol Chem
285:1634–1642
Yang LB, Lindholm K, Yan R et al (2003) Elevated beta-secretase
expression and enzymatic activity detected in sporadic Alzheimer
disease. Nat Med 9:3–4
Zhang L, Song L, Parker EM (1999) Calpain inhibitor I increases
beta-amyloid peptide production by inhibiting the degradation of
the substrate of gamma-secretase. Evidence that substrate
availability limits beta-amyloid peptide production. J Biol Chem
274:8966–8972
J Mol Neurosci (2011) 43:257–267 267